Adverse Events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Veriton Pharma Ltd.
Tel: + 44 (0)1932 690325.

         You are now leaving this website.

Veriton Pharma Ltd is not responsible for the information on the website to which you are linking.

CONTINUE

Approval stamp to illustrate Epistatus 10mg/1mL PFS now approved by SMC and AWMSG
www.Epistatus.co.uk

10mg in 1mL Oromucosal Solution
Midazolam (as maleate)

 

Epistatus® (oromucosal midazolam) is licensed for the treatment of prolonged,
acute convulsive seizures in children and adolescents aged 10 to less than 18 years
who have been diagnosed with epilepsy.

Photo of Epistatus 10 mg pack
 
ABOUT
EPISTATUS
-
Midazolam
Protocol
-
REQUEST
TRAINING PACK
-
ACCESSING
EPISTATUS FOR
YOUR PATIENTS
-
TREATMENT OF
PROLONGED, ACUTE
CONVULSIVE SEIZURES
-
BUDGET
IMPACT MODEL
-
HOW TO
ADMINISTER EPISTATUS
-
EPISTATUS FAQ
-
EPISTATUS
DEMONSTRATION
VIDEO
-
RESOURCES
-
 
Epistatus 10mg in 1mL oromucosal solution midazolam (as maleate) brand logo
10mg in 1mL Oromucosal Solution
Midazolam (as maleate)
Veriton Pharma brand logo

© 2017 Veriton Pharma Ltd. All Rights Reserved. Please read the Legal Notice for further details. Company Registration No. 03305136.

This website is produced and maintained by Veriton Pharma Ltd. and includes promotional content.

This information is intended only for the use of healthcare professionals in the United Kingdom. If you are not a healthcare professional, please click here.

Item code number EDM-1022-2019. Date of preparation: March 2019.

Prescribing information

Summary of product characteristics

Report an adverse event

Site map

Contact us

Privacy policy

Terms and conditions